M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma.
Bottom-up MS
M protein
Minimal residual disease
Multiple myeloma
Top-down MS
Journal
Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422
Informations de publication
Date de publication:
02 Nov 2023
02 Nov 2023
Historique:
received:
07
08
2023
revised:
28
10
2023
accepted:
30
10
2023
pubmed:
5
11
2023
medline:
5
11
2023
entrez:
4
11
2023
Statut:
aheadofprint
Résumé
Multiple myeloma (MM) is characterized by excessive production of monoclonal immunoglobulins (M proteins). Routine screening methods for M proteins to assess prognosis are unable to detect low levels of M proteins produced by residual tumor cells, ie, minimal residual disease (MRD). Assessment of MRD can be conducted by examining residual tumor cells in bone marrow or circulating M proteins. Advances in mass spectrometry have enabled reliable and highly sensitive detection of low abundance serum biomarkers making it a viable and significantly less invasive approach. Mass spectrometry can achieve dynamic monitoring of MRD and identify therapeutic monoclonal antibodies as well as oligoclonal proteins. In this review we summarize mass spectrometry methods in M protein detection and their applications of MRD detection in MM.
Identifiants
pubmed: 37924928
pii: S0009-8981(23)00425-4
doi: 10.1016/j.cca.2023.117623
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
117623Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.